Short Interest in Health Catalyst, Inc. (NASDAQ:HCAT) Increases By 8.8%

Health Catalyst, Inc. (NASDAQ:HCAT) saw a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 2,840,000 shares, a growth of 8.8% from the October 15th total of 2,610,000 shares. Based on an average trading volume of 473,600 shares, the short-interest ratio is currently 6.0 days.

Health Catalyst Price Performance

NASDAQ:HCAT opened at $7.53 on Tuesday. Health Catalyst has a 52 week low of $5.42 and a 52 week high of $11.41. The stock’s fifty day moving average is $8.16 and its two-hundred day moving average is $7.24. The company has a market capitalization of $458.19 million, a P/E ratio of -5.58 and a beta of 1.32. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). The company had revenue of $76.40 million during the quarter, compared to analysts’ expectations of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The firm’s quarterly revenue was up 3.5% on a year-over-year basis. During the same quarter last year, the firm posted ($0.22) earnings per share. Equities analysts expect that Health Catalyst will post -0.35 EPS for the current year.

Insiders Place Their Bets

In related news, insider Kevin Lee Freeman sold 7,500 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the transaction, the insider now owns 255,881 shares in the company, valued at $1,847,460.82. This represents a 2.85 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Daniel Lesueur sold 5,209 shares of the firm’s stock in a transaction dated Thursday, October 3rd. The shares were sold at an average price of $7.68, for a total transaction of $40,005.12. Following the completion of the transaction, the chief operating officer now directly owns 134,899 shares in the company, valued at $1,036,024.32. This represents a 3.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 34,068 shares of company stock worth $257,555. Company insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Health Catalyst

A number of hedge funds have recently made changes to their positions in the stock. Principal Financial Group Inc. lifted its stake in Health Catalyst by 6.9% during the second quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock worth $188,000 after purchasing an additional 1,907 shares in the last quarter. Harbor Capital Advisors Inc. raised its holdings in shares of Health Catalyst by 21.3% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company’s stock valued at $96,000 after buying an additional 2,064 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in Health Catalyst by 10.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,162 shares of the company’s stock valued at $148,000 after acquiring an additional 2,164 shares during the period. Creative Planning grew its position in Health Catalyst by 13.2% in the 3rd quarter. Creative Planning now owns 21,348 shares of the company’s stock valued at $174,000 after acquiring an additional 2,486 shares in the last quarter. Finally, Quarry LP grew its position in Health Catalyst by 59.4% in the 2nd quarter. Quarry LP now owns 7,002 shares of the company’s stock valued at $45,000 after acquiring an additional 2,610 shares in the last quarter. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on HCAT shares. Citigroup increased their price objective on Health Catalyst from $9.00 to $10.50 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Royal Bank of Canada boosted their price target on shares of Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. increased their price objective on shares of Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a report on Wednesday, September 4th. Cantor Fitzgerald restated an “overweight” rating and set a $16.00 target price on shares of Health Catalyst in a report on Friday, October 4th. Finally, Stephens upped their price target on Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a research report on Thursday, November 14th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $11.71.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.